{"data":[{"accessionNo":"0000921895-26-002166","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":6491123,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-002166","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":6491123,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-002166","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":6491123,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-002166","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":5980450,"percentOfClass":9.2,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000080255-26-000574","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics Inc","ticker":"CGEM","cusip":"230031106","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":3825950,"percentOfClass":6.2,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-002166","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":3711284,"percentOfClass":5.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-002166","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":3711284,"percentOfClass":5.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-002166","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":2269166,"percentOfClass":3.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-002166","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":2269166,"percentOfClass":3.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-002166","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":400861,"percentOfClass":0.6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-002166","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":400861,"percentOfClass":0.6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000093751-26-000446","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001789972","issuerName":"CULLINAN THERAPEUTICS INC","ticker":"CGEM","cusip":"230031106","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":3668627,"percentOfClass":6,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-001387","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":6161469,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-001387","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":6161469,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-001387","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":6161469,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-001387","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":5824331,"percentOfClass":9.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-001387","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":3551482,"percentOfClass":5.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-001387","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":3551482,"percentOfClass":5.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-001387","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":2272849,"percentOfClass":3.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-001387","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":2272849,"percentOfClass":3.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-001387","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":224641,"percentOfClass":0.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-001387","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":224641,"percentOfClass":0.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000102909-26-001005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics Inc","ticker":"CGEM","cusip":"230031106","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-26","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001907884-26-000005","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Kynam Capital Management, LP","reportingCik":null,"personType":"IA","sharesOwned":3114132,"percentOfClass":5.27,"filedAt":"2026-03-04","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001907884-26-000005","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Kynam Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":3114132,"percentOfClass":5.27,"filedAt":"2026-03-04","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001907884-26-000005","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Yue Tang","reportingCik":null,"personType":"IN","sharesOwned":3114132,"percentOfClass":5.27,"filedAt":"2026-03-04","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-000457","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":5918481,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-000457","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":5918481,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-000457","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":5918481,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-000457","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":5574038,"percentOfClass":9.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-000457","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":3302376,"percentOfClass":5.6,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-000457","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":3302376,"percentOfClass":5.6,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-000457","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":2271662,"percentOfClass":3.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-000457","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":2271662,"percentOfClass":3.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-000457","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":224641,"percentOfClass":0.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000921895-26-000457","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":224641,"percentOfClass":0.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000102909-26-000065","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics Inc","ticker":"CGEM","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":3298504,"percentOfClass":5.58,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000902664-25-004966","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"LYNX1 CAPITAL MANAGEMENT LP","reportingCik":null,"personType":"PN","sharesOwned":5766090,"percentOfClass":9.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000902664-25-004966","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"WESTON NICHOLS","reportingCik":null,"personType":"IN","sharesOwned":5766090,"percentOfClass":9.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001104659-25-112463","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Kenneth Griffin","reportingCik":null,"personType":"HC,IN","sharesOwned":1988907,"percentOfClass":3.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001104659-25-112463","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":1841079,"percentOfClass":3.1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001104659-25-112463","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Advisors LLC","reportingCik":null,"personType":"IA,HC,OO","sharesOwned":1841079,"percentOfClass":3.1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001104659-25-112463","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Advisors Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":1841079,"percentOfClass":3.1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001104659-25-112463","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Securities LLC","reportingCik":null,"personType":"BD,OO","sharesOwned":147828,"percentOfClass":0.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001104659-25-112463","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Securities Group LP","reportingCik":null,"personType":"HC,PN","sharesOwned":147828,"percentOfClass":0.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001104659-25-112463","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Securities GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":147828,"percentOfClass":0.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001193805-25-001585","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Deerfield Mgmt, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2927013,"percentOfClass":4.95,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001193805-25-001585","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Deerfield Management Company, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2927013,"percentOfClass":4.95,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001193805-25-001585","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Deerfield Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2927013,"percentOfClass":4.95,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0001193805-25-001585","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"James E. Flynn","reportingCik":null,"personType":"IN","sharesOwned":2927013,"percentOfClass":4.95,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000102909-25-000125","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics Inc","ticker":"CGEM","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":2943325,"percentOfClass":4.98,"filedAt":"2025-10-30","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000902664-25-004377","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-08","reportingPerson":"Lynx1 Capital Management LP","reportingCik":null,"personType":"PN","sharesOwned":8549084,"percentOfClass":14.5,"filedAt":"2025-10-10","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"},{"accessionNo":"0000902664-25-004377","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001789972","issuerName":"Cullinan Therapeutics, Inc.","ticker":"CGEM","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-08","reportingPerson":"Weston Nichols","reportingCik":null,"personType":"IN","sharesOwned":8549084,"percentOfClass":14.5,"filedAt":"2025-10-10","canonicalUrl":"https://xoomar.com/markets/stocks/cgem"}],"updatedAt":"2026-11-03T22:37:54.930Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/cgem","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}